COYA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

4.878

Open

4.430

VWAP

4.72

Vol

110.28K

Mkt Cap

101.27M

Low

4.430

Amount

520.06K

EV/EBITDA(TTM)

--

Total Shares

20.92M

EV

85.35M

EV/OCF(TTM)

--

P/S(TTM)

20.19

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.

Show More

Events Timeline

(ET)

2026-01-30

08:20:00

Coya Therapeutics Completes Private Placement of 2.522M Shares

2026-01-05 (ET)

2026-01-05

08:10:00

Coya Therapeutics' COYA 302 New Drug Application Accepted by FDA

2025-12-23 (ET)

2025-12-23

08:10:00

Coya Therapeutics Receives Health Canada Approval for COYA 302 Clinical Trial

2025-12-09 (ET)

2025-12-09

08:10:00

Coya Therapeutics Commences Dosing of ALS Patients in ALSTARS Trial of COYA 302

2025-11-12 (ET)

2025-11-12

08:18:45

Coya Therapeutics announces Q3 earnings per share of 13 cents, below consensus estimate of 30 cents.

2025-11-04 (ET)

2025-11-04

09:02:27

Coya Therapeutics Reveals Findings from In Vivo Animal Study of COYA 303

2025-10-24 (ET)

2025-10-24

06:33:39

Coya Therapeutics Sets Price for $3.64M Spot Secondary at $5.50

2025-10-23 (ET)

2025-10-23

16:33:31

Coya Therapeutics Reveals Common Stock Offering, Amount Not Disclosed

2025-09-29 (ET)

2025-09-29

08:09:47

Coya Therapeutics finishes participant enrollment for IL-2 and CTLA4-Ig study

News

seekingalpha

01-30seekingalpha

Coya Therapeutics Secures $11.1 Million in Private Placement

Yahoo Finance

01-30Yahoo Finance

Coya Therapeutics Secures $11.1 Million in Private Placement

Newsfilter

01-05Newsfilter

Coya Therapeutics Receives FDA IND Approval for COYA 302 to Treat Frontotemporal Dementia

Benzinga

2025-11-12Benzinga

D. Boral Capital Reiterates Buy Rating for Coya Therapeutics with $15 Price Target Intact

Newsfilter

2025-10-24Newsfilter

Coya Therapeutics Reveals Pricing for Increased $20 Million Public Offering of Common Stock

SeekingAlpha

2025-10-24SeekingAlpha

Coya Therapeutics Declines Following $20M Stock Offering Announcement

3 Analyst Rating

Wall Street analysts forecast COYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COYA is 17.00 USD with a low forecast of 16.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

16.00

Averages

17.00

High

18.00

Current: 0.000

Low

16.00

Averages

17.00

High

18.00

Lake Street

Buy

maintain

$16 -> $17

AI Analysis

2025-11-05

Reason

Lake Street

Price Target

$16 -> $17

AI Analysis

2025-11-05

maintain

Buy

Reason

Lake Street raised the firm's price target on Coya Therapeutics to $17 from $16 and keeps a Buy rating on the shares after the company released preclinical in vivo neuroinflammation data for COYA-303 consistent with earlier in vitro preclinical results released by Coya.

Lake Street

NULL -> Buy

initiated

$16

2025-07-09

Reason

Lake Street

Price Target

$16

2025-07-09

initiated

NULL -> Buy

Reason

Lake Street initiated coverage of Coya Therapeutics with a Buy rating and $16 price target. The firm says the company's anti-inflammation platform utilizes a disease pathway agnostic approach to increase the number and function of regulatory T cells. The evidence supporting a therapeutic anti-inflammatory benefit of Coya's low dose IL-2 is strong, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for COYA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Coya Therapeutics Inc (COYA.O) is -3.78, compared to its 5-year average forward P/E of -7.05. For a more detailed relative valuation and DCF analysis to assess Coya Therapeutics Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-7.05

Current PE

-3.78

Overvalued PE

1.71

Undervalued PE

-15.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.69

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.96

Undervalued EV/EBITDA

-4.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

19.67

Current PS

50.16

Overvalued PS

35.76

Undervalued PS

3.58

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

can you limit the choices to only 5 stocks

Intellectia · 724 candidates

Price: <= $10.00Pe Ttm: <= 15Target Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

Flux Power Holdings Inc

31.80M

Organogenesis Holdings Inc

487.34M

Sangamo Therapeutics Inc

127.97M

Aquestive Therapeutics Inc

409.93M

Traws Pharma Inc

19.42M

BTCS Inc

126.36M

Whales Holding COYA

Greenlight Capital, Inc.

Trading Trends

People Also Watch

Frequently Asked Questions

What is Coya Therapeutics Inc (COYA) stock price today?

The current price of COYA is 4.84 USD — it has increased 9.5 % in the last trading day.

What is Coya Therapeutics Inc (COYA)'s business?

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.

What is the price predicton of COYA Stock?

Wall Street analysts forecast COYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COYA is17.00 USD with a low forecast of 16.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Coya Therapeutics Inc (COYA)'s revenue for the last quarter?

Coya Therapeutics Inc revenue for the last quarter amounts to 3.56M USD, decreased % YoY.

What is Coya Therapeutics Inc (COYA)'s earnings per share (EPS) for the last quarter?

Coya Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, decreased -50.00 % YoY.

How many employees does Coya Therapeutics Inc (COYA). have?

Coya Therapeutics Inc (COYA) has 8 emplpoyees as of February 09 2026.

What is Coya Therapeutics Inc (COYA) market cap?

Today COYA has the market capitalization of 101.27M USD.